Clinical Trial Update: Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing two sirolimus-based regimens with a tacrolimus plus mycophenolate mofetil regimen in kidney transplant recipients to evaluate graft outc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Renal Allograft Rejection

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Prograf (Tacrolimus)
• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Graft Rejection, Kidney Failure | Phase 4 | Status: COMPLETED